Welcome to our dedicated page for Akoya Biosciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya Biosciences stock.
Akoya Biosciences, Inc. (AKYA), known as The Spatial Biology Company®, generates news that spans technology developments, collaborations, financial reporting, and corporate transactions. Company announcements emphasize its single-cell imaging and spatial proteomics platforms, which are used to phenotype cells with spatial context and study how they organize and interact in disease. News items often describe how Akoya’s PhenoCode™ Panels, PhenoCycler®, Phenor® Fusion, and Phenor HT instruments are applied across discovery, translational, and clinical research.
Investors and researchers following AKYA-related news will find updates on spatial biology and proteomics initiatives, including large-scale projects and partnerships. Recent releases highlight collaborations such as the Cancer Grand Challenges-funded study using PhenoCycler-Fusion, the SUPER study with the Singapore Translational Cancer Consortium leveraging the IO60 panel to investigate PD-1 immunotherapy response, and the Enable Medicine Pan-Cancer Atlas built on Akoya’s PhenoCycler-Fusion and IO60 technologies. These stories illustrate how Akoya’s platforms are integrated into biomarker discovery, drug development, and precision oncology efforts.
News coverage has also included financial results and operational updates, such as quarterly revenue composition, changes in operating expenses, and growth in the installed base of instruments and publications citing Akoya’s technology. In addition, corporate and capital markets news has been prominent, particularly the Amended and Restated Agreement and Plan of Merger with Quanterix Corporation and subsequent shareholder and activist responses to that transaction.
Following the completion of the merger on July 8, 2025, Akoya became a wholly owned subsidiary of Quanterix, and its common stock was removed from listing on Nasdaq. The AKYA news stream therefore serves as a historical archive of Akoya’s activities as an independent public company, covering its evolution in spatial biology, its collaborations, and the steps leading to its acquisition by Quanterix.
Akoya Biosciences (Nasdaq: AKYA) announced the shipment of its 1,000th instrument, marking a significant milestone and establishing the largest installed base in the spatial biology industry. This achievement highlights the widespread adoption of Akoya's technologies in research laboratories globally and sets the stage for clinical applications. The portfolio features advanced tools such as PhenoCycler®, PhenoImager® Fusion, and PhenoImager HT, enabling precise spatial biomarker identification. CEO Brian McKelligon expressed gratitude to the team for their role in this success and reiterated the commitment to expanding their ecosystem of spatial biology solutions. The 1,000th system was delivered to iHisto, a histopathology lab known for high-quality services and innovative technologies.
Akoya Biosciences, Inc. (Nasdaq: AKYA) has launched the PhenoCode Discovery Panels at the AACR 2023 Annual Meeting in Orlando, aimed at advancing cancer research. These panels facilitate the analysis of tumors and their microenvironment by providing ready-to-use biomarker combinations for immune profiling and tissue architecture assessment. They significantly reduce assay development time, accelerating spatial discovery by up to three times compared to traditional workflows. The company plans to expand its product offerings with more protein biomarker panels throughout 2023 and 2024, along with launching RNA panels in the latter half of 2023. Akoya's innovations aim to streamline workflows for researchers and enhance the capabilities of the PhenoCycler-Fusion platform.
FAQ
What is the current stock price of Akoya Biosciences (AKYA)?
What is the market cap of Akoya Biosciences (AKYA)?
